Welcome to Alimera Sciences Europe

Alimera Sciences, founded in June 2003, and proudly established in Europe since 2013, is a pharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our ageing populations.

Our commitment to ophthalmologists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

Alimera's focus is to:

  • Continue development of our current product portfolio in pursuit of other potential ophthalmic indications.

  • Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.

  • Operate as an ethically driven company, recognising our responsibility to others and the importance of having a positive impact on those with whom we interact.

Leadership team

The Alimera Sciences management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and is dedicated and focused in making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive development and commercialisation of ophthalmic products.

Executive Leadership


Oliver Trendelenburg

Managing Director, Germany

Oliver Trendelenburg is Managing Director of Alimera Sciences Ophthalmology GmbH Germany since the beginning of 2015. He began his career at the former Schering AG (now Bayer HealthCare Pharmaceuticals) in Berlin and held various executive roles in Marketing and Commercialisation of Specialised Therapeutic Drugs both in Germany as well as several years in the USA. He has 18 years of management experience in the Pharmaceutical Industry and holds a degree in Business Administrations and Economics, accompanied with stays abroad.


Carlos Augusto

Managing Director, Portugal & Spain

Carlos Augusto joined Alimera Sciences as Country Manager Portugal in July 2014. 2015 has seen his responsibilities extend to management of Alimera Sciences activities in Spain. He has 16 years of experience in the Pharmaceutical Industry in several Sales and Marketing Managerial roles across different companies. He started his experience in Ophthalmology in 2008 at Merck Sharp & Dohme Portugal, where he held roles in Marketing and Sales. Carlos holds a degree in Marketing Management.


Global Leadership

Dan Myers

Dan Myers

Chief Executive Officer

Dan Myers is one of our co-founders and has served as our Chief Executive Officer and as a director since the founding of our Company in 2003. Before founding our Company, Mr. Myers was an employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003. Mr. Myers holds a Bachelor of Science in Industrial Management from Georgia Institute of Technology.

Mr. Myers has over 33 years of ophthalmic pharmaceutical experience, including over 19 years in the role of President or Chief Executive Officer. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc. from 2009 to 2012. Mr. Myers currently serves on a number of industry boards.


Philip Ashman, Ph.D.

Senior Vice President and European Managing Director

Philip Ashman, Ph.D. has served as the Senior Vice President, Managing Director Europe since January 1, 2013. Prior to joining us, Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, most recently responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including Ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa.

Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in Biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in Biochemistry from the University College London, U.K.

Rick Eiswirth

Richard S. Eiswirth, Jr.

President and Chief Financial Officer

Richard S. Eiswirth, Jr. has served as President and Chief Financial Officer of our Company since January 2016. Mr. Eiswirth previously served as our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999.

Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as Chairman, Audit Committee Chairman and member of the Compensation Committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a Bachelor of Arts in Accounting from Wake Forest University.

Ken Green

Kenneth Green, Ph.D. 

Senior Vice President and Chief Scientific Officer

Kenneth Green, Ph.D. joined us in 2004 as Vice President of Scientific Affairs, and has served as the Senior Vice President and Chief Scientific Officer of our Company since January 2007. Prior to joining us, Dr. Green served as the Vice President Global Head of Clinical Sciences at Novartis Ophthalmics. He has managed ophthalmic clinical development organizations at Storz Ophthalmics, Bausch & Lomb and CIBA Vision. He started his career in the pharmaceutical industry in 1984, as a basic research scientist in drug discovery at Lederle Laboratories, and has since held positions in many areas of drug development.

Dr. Green holds a Bachelor of Arts in Chemistry from Southern Illinois University and a Ph.D. in Organic Chemistry from Ohio State University.

Dave Holland

David Holland

Senior Vice President of Sales and Marketing

David Holland is one of our co-founders and served as the Vice President of Marketing since the founding of our Company in 2003 through August 2010 when he was appointed the Senior Vice President of Sales and Marketing.

Prior to founding our Company, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds a Bachelor of Arts in Politics from Princeton University.

For more information Contact us